
Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, projected growth trends, production technology, application and end-user industry.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company
Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type
Lenograstim
Pegfilgrastim
Other
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application
Hospital and Clinic
Pharmacy
Other
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, projected growth trends, production technology, application and end-user industry.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company
Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type
Lenograstim
Pegfilgrastim
Other
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application
Hospital and Clinic
Pharmacy
Other
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
209 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
- 1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Lenograstim
- 1.2.3 Pegfilgrastim
- 1.2.4 Other
- 1.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
- 1.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Hospital and Clinic
- 1.3.3 Pharmacy
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
- 2.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
- 2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
- 2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
- 2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region
- 3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2020-2025)
- 3.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2026-2031)
- 3.2.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2020-2031)
- 3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Estimates and Forecasts 2020-2031
- 3.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region
- 3.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2020-2025)
- 3.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2026-2031)
- 3.4.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers
- 4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers
- 4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (2020-2025)
- 4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Price by Manufacturers (2020-2025)
- 4.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application
- 4.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market CR5 and HHI
- 4.8.2 2024 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3
- 5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
- 5.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type
- 5.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2020-2031)
- 5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type
- 5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020-2031) & (K Units)
- 5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2020-2031)
- 5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type
- 6 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
- 6.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application
- 6.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2020-2031)
- 6.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application
- 6.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020-2031) & (K Units)
- 6.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2020-2031)
- 6.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application
- 7 Company Profiles
- 7.1 Amgen
- 7.1.1 Amgen Comapny Information
- 7.1.2 Amgen Business Overview
- 7.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.1.5 Amgen Recent Developments
- 7.2 Mylan
- 7.2.1 Mylan Comapny Information
- 7.2.2 Mylan Business Overview
- 7.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.2.5 Mylan Recent Developments
- 7.3 Kashiv BioSciences
- 7.3.1 Kashiv BioSciences Comapny Information
- 7.3.2 Kashiv BioSciences Business Overview
- 7.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.3.5 Kashiv BioSciences Recent Developments
- 7.4 Pfizer
- 7.4.1 Pfizer Comapny Information
- 7.4.2 Pfizer Business Overview
- 7.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.4.5 Pfizer Recent Developments
- 7.5 Fresenius Kabi
- 7.5.1 Fresenius Kabi Comapny Information
- 7.5.2 Fresenius Kabi Business Overview
- 7.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.5.5 Fresenius Kabi Recent Developments
- 7.6 Coherus BioSciences
- 7.6.1 Coherus BioSciences Comapny Information
- 7.6.2 Coherus BioSciences Business Overview
- 7.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.6.5 Coherus BioSciences Recent Developments
- 7.7 Sandoz
- 7.7.1 Sandoz Comapny Information
- 7.7.2 Sandoz Business Overview
- 7.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.7.5 Sandoz Recent Developments
- 7.8 Italfarmaco SpA
- 7.8.1 Italfarmaco SpA Comapny Information
- 7.8.2 Italfarmaco SpA Business Overview
- 7.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.8.5 Italfarmaco SpA Recent Developments
- 7.9 Evive Biotech
- 7.9.1 Evive Biotech Comapny Information
- 7.9.2 Evive Biotech Business Overview
- 7.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.9.5 Evive Biotech Recent Developments
- 7.10 Chugai Pharmaceutical
- 7.10.1 Chugai Pharmaceutical Comapny Information
- 7.10.2 Chugai Pharmaceutical Business Overview
- 7.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.10.5 Chugai Pharmaceutical Recent Developments
- 7.11 Jiangsu Hengrui Pharmaceuticals
- 7.11.1 Jiangsu Hengrui Pharmaceuticals Comapny Information
- 7.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 7.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 7.12 Amoytop Biotech
- 7.12.1 Amoytop Biotech Comapny Information
- 7.12.2 Amoytop Biotech Business Overview
- 7.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.12.5 Amoytop Biotech Recent Developments
- 7.13 Qilu Pharmaceutical
- 7.13.1 Qilu Pharmaceutical Comapny Information
- 7.13.2 Qilu Pharmaceutical Business Overview
- 7.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.13.5 Qilu Pharmaceutical Recent Developments
- 7.14 CSPC Baike Biopharma
- 7.14.1 CSPC Baike Biopharma Comapny Information
- 7.14.2 CSPC Baike Biopharma Business Overview
- 7.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.14.5 CSPC Baike Biopharma Recent Developments
- 7.15 SL Pharm
- 7.15.1 SL Pharm Comapny Information
- 7.15.2 SL Pharm Business Overview
- 7.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.15.5 SL Pharm Recent Developments
- 7.16 Lunan Pharmaceutical
- 7.16.1 Lunan Pharmaceutical Comapny Information
- 7.16.2 Lunan Pharmaceutical Business Overview
- 7.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
- 7.16.5 Lunan Pharmaceutical Recent Developments
- 8 North America
- 8.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
- 8.1.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020-2031)
- 8.1.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020-2031)
- 8.1.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2020-2031)
- 8.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
- 8.2.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020-2031)
- 8.2.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020-2031)
- 8.2.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2020-2031)
- 8.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
- 8.3.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
- 9 Europe
- 9.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
- 9.1.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020-2031)
- 9.1.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020-2031)
- 9.1.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2020-2031)
- 9.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
- 9.2.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020-2031)
- 9.2.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020-2031)
- 9.2.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2020-2031)
- 9.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
- 9.3.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
- 10 China
- 10.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
- 10.1.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020-2031)
- 10.1.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020-2031)
- 10.1.3 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2020-2031)
- 10.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
- 10.2.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020-2031)
- 10.2.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020-2031)
- 10.2.3 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
- 11.1.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020-2031)
- 11.1.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020-2031)
- 11.1.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2020-2031)
- 11.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
- 11.2.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020-2031)
- 11.2.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020-2031)
- 11.2.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2020-2031)
- 11.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
- 11.3.1 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Type
- 12.1.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2020-2031)
- 12.1.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2020-2031)
- 12.1.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2020-2031)
- 12.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Application
- 12.2.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2020-2031)
- 12.2.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2020-2031)
- 12.2.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2020-2031)
- 12.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country
- 12.3.1 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
- 13.1.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
- 13.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
- 13.2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.